CD8 T cells control cytomegalovirus (CMV) infection in bone marrow transplantation recipients and persist in latently infected lungs as effector memory cells for continuous sensing of reactivated viral gene expression.Here we have addressed the question of whether viral immunoevasins, glycoproteins that specifically interfere with antigen presentation to CD8 T cells, have an impact on viral latency in the murine model. The data show that deletion of immunoevasin genes in murine CMV accelerates the clearance of productive infection during hematopoietic reconstitution and leads to a reduced latent viral genome load, reduced latency-associated viral transcription, and a lower incidence of recurrence in lung explants.Establishment of latency after clearance of acute infection and the potential to reactivate to recurrent infection are key features of herpesvirus pathogenicity (41). Cytomegaloviruses (CMVs) are usually well controlled by the immune system and cause acute as well as recurrent disease mainly in the immunocompromised or immunologically immature host. Recipients (R) of bone marrow transplantation (BMT) are at risk of reactivating intrinsic human CMV (hCMV) or of becoming infected by reactivating donor (D)-derived hCMV transmitted with the transplant or of both (constellations, respectively) (9). Clinical studies (32, 38) and experimental studies of the murine model of infection with murine CMV (mCMV) (18; reviewed in reference 16) have consistently shown that timely endogenous lymphohematopoietic reconstitution of antiviral CD8 T cells is decisive for coping with CMV infection after BMT. Accordingly, preemptive immunotherapy with antiviral CD8 T cells proved to be a promising approach with the murine model (3,14,35,36,44) and in clinical trials (6,27,40). Both viruses hCMV and mCMV express proteins, so-called immunoevasins, that interfere with the major histocompatibility complex class I pathway of antigen presentation to CD8 T cells (reviewed in reference 33). Whereas many studies have demonstrated the efficacy of immunoevasins in inhibiting the cell surface presentation of antigenic peptides in infected cells in vitro, these molecules do not prevent (11,19,26) but rather enhance (4) the priming of viral epitope-specific CD8 T cells, and their role and relevance in viral pathogenesis in vivo are a currently discussed issue (8). Obviously, research on the in vivo function of immunoevasins by using viral immunoevasin gene deletion mutants can be accomplished only using animal models, and the murine model is well established. Although the detailed molecular modes of action differ between the immunoevasins of hCMV and mCMV, the biological outcome in